Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UEA Enterprises Limited has 4 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among 4 examiners and 4 art units, so the prosecution profile spans separate examination assignments rather than a single channel.
KIFLE, BRUCK is the busiest examiner, with 1 pending matter. No examiner has more than that figure in the supplied data, which indicates an even distribution of the pending matters across the identified examiners. Counsel should therefore track each assignment independently instead of treating one examiner as the principal point of contact.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860392 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | KIFLE, BRUCK | — |
| 18696137 | DRY CREAMS AND TOPICAL DELIVERY SYSTEMS | WAX, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17441849 | PHOTOACTIVE ANTIBODIES | LI, RUIXIANG | 98d overdue |
| 18860392 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | KIFLE, BRUCK | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1615 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860392 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | KIFLE, BRUCK | 1629 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18696137 | DRY CREAMS AND TOPICAL DELIVERY SYSTEMS | WAX, ROBERT A | 1615 | §103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 17441849 | PHOTOACTIVE ANTIBODIES | LI, RUIXIANG | 1674 | §112 | Final Rejection | 98d overdue | Pending | Sep 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUEA Enterprises Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Bruck Kifle has the most, with 1 of UEA Enterprises Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
